

# Stimulation by Nitric Oxide Synthase Inhibitors of Gastric and Duodenal $\text{HCO}_3^-$ Secretion in Rats

KOJI TAKEUCHI, TOMOHISA OHUCHI, HIROKI MIYAKE and SUSUMU OKABE

Department of Applied Pharmacology, Kyoto Pharmaceutical University, Misasagi, Yamashina, Japan

Accepted for publication May 20, 1993

## ABSTRACT

The role of nitric oxide (NO) in the regulation of gastroduodenal  $\text{HCO}_3^-$  secretion was investigated in anesthetized rats using the NO biosynthesis inhibitor  $\text{N}^G$ -nitro-L-arginine methyl ester (L-NAME).  $\text{HCO}_3^-$  secretion was measured at pH 7.0 using a pH-stat method in the chambered stomach in the presence of omeprazole or in the proximal duodenum. Intravenous administration of L-NAME (1–5 mg/kg) increased  $\text{HCO}_3^-$  secretion in a dose-dependent manner in both the stomach and duodenum, with a concomitant elevation of arterial blood pressure. The stimulatory effect of L-NAME on  $\text{HCO}_3^-$  secretion was mimicked by another NO synthase inhibitor,  $\text{N}^G$ -monomethyl-L-arginine (50 mg/kg), but not by the enantiomer  $\text{N}^G$ -nitro-D-arginine methyl ester, and was significantly antagonized by concurrent administration of L-arginine, but not D-arginine, at 200 mg/kg. The

exogenous NO donor nitroprusside (4 mg/kg) by itself decreased the rate of  $\text{HCO}_3^-$  secretion and significantly antagonized the  $\text{HCO}_3^-$  stimulatory action of L-NAME. Furthermore, the increased  $\text{HCO}_3^-$  secretion caused by L-NAME was significantly attenuated by prior administration of atropine (1 mg/kg, s.c.) or indomethacin (5 mg/kg, s.c.) and by bilateral vagotomy but was not influenced by sensory deafferentation after capsaicin pretreatment, though none of the treatments had any effect on the changes in blood pressure induced by L-NAME. These results suggest that L-NAME stimulates  $\text{HCO}_3^-$  secretion in the gastroduodenal mucosa. This action is associated with the inhibition of NO biosynthesis and may be partly dependent on vagal-cholinergic innervation and mediated by endogenous prostaglandins.

$\text{HCO}_3^-$  secretion from the surface epithelial cells is considered one of the defensive factors in the gastroduodenal mucosa (Flemstrom and Turnberg, 1984; Garner *et al.*, 1984). PGs and their derivatives, which confer protection of the mucosa against acid, increase  $\text{HCO}_3^-$  secretion as well as mucosal blood flow (Robert, 1981; Garner *et al.*, 1984). On the other hand, nitric oxide (NO), which accounts for the biological actions of endothelium-derived relaxing factor and is the endogenous stimulator of the soluble guanylate cyclase (Furchgott, 1984), is now known to be generated in various other cells, including the epithelium, mast cells, macrophages and enteric neurons (Moncada *et al.*, 1991), and mimics the protective action of PGs in the gastric mucosa (Pique *et al.*, 1989; Whittle *et al.*, 1990; Lippe *et al.*, 1992). Unexpectedly, we found in a preliminary study that one of the NO synthase inhibitors, L-NAME, increased  $\text{HCO}_3^-$  secretion in the stomach, suggesting that NO formed endogenously may play a role in modulation of the mucosa's ability to secrete  $\text{HCO}_3^-$  under pathophysiological conditions (Takeuchi *et al.*, 1992b). However, the mechanism underlying the increase of  $\text{HCO}_3^-$  secretion brought about by the inhibition of NO production remains unknown.

In the present study, we examined the effects of L-NAME on  $\text{HCO}_3^-$  secretion from the gastroduodenal mucosa of anesthetized rats and characterized these effects with regard to inhibition of NO biosynthesis and relation to such  $\text{HCO}_3^-$  stimulatory pathways as endogenous PGs and the vagal-cholinergic mechanism.

## Materials and Methods

**Animals.** Male Sprague-Dawley rats weighing 230 to 250 g (Charles River, Shizuoka, Japan) were used. The animals were kept in individual cages with raised mesh bottoms to prevent coprophagia, and they were deprived of food but were allowed free access to tap water for 18 hr before the experiments. All studies were carried out using 5 to 6 animals per group under anesthetized conditions induced by i.p. administration of urethane (1.25 g/kg).

**Determination of gastric and duodenal  $\text{HCO}_3^-$  secretion.** Gastric and duodenal  $\text{HCO}_3^-$  secretion was determined in the chambered stomach and in the duodenal loop according to previously published methods (Takeuchi *et al.*, 1986; 1992a). Briefly, the abdomen was incised, and the stomach was exposed, mounted on a chamber (exposed area: 3.1  $\text{cm}^2$ ) and perfused with saline that was gassed with 100%  $\text{O}_2$  and kept in a reservoir. Gastric alkaline secretion was measured at pH 7.0 by using a pH-stat method (Hiranuma Comtite-7, Mito, Japan) and by adding 10 mM HCl to the reservoir. To unmask  $\text{HCO}_3^-$  in the

Received for publication February 12, 1993.

**ABBREVIATIONS:** PGs, prostaglandins;  $\text{PGE}_2$ , prostaglandin  $\text{E}_2$ ; D-NAME,  $\text{N}^G$ -nitro-D-arginine methyl ester; L-NAME,  $\text{N}^G$ -nitro-L-arginine methyl ester; L-NMMA,  $\text{N}^G$ -monomethyl-L-arginine; cyclic AMP, adenosine-3',5'-cyclic monophosphate; cyclic GMP, guanosine-3',5'-cyclic monophosphate.

stomach acid, secretion was completely inhibited by omeprazole given i.p. in a dose of 60 mg/kg. On the other hand, the duodenal loop (1.7 cm) was made between the pyloric ring and the area just above the outlet of the common bile duct in order to exclude the influences of bile and pancreatic juice. Then the loop was perfused with saline as described for the gastric preparation, and HCO<sub>3</sub><sup>-</sup> secretion was measured at pH 7.0 by using the pH-stat system and by adding 10 mM HCl to the reservoir. In some animals, arterial blood pressure (BP) was monitored through a femoral artery by a pressure transducer and amplifier system (San-ei, type 45277, Tokyo, Japan). After basal HCO<sub>3</sub><sup>-</sup> secretion had stabilized, the following agents were given i.v. as a bolus injection: PGE<sub>2</sub> (0.3 mg/kg), L-NAME (1, 2.5 and 5 mg/kg), D-NAME (5 mg/kg) and L-NMMA (50 mg/kg). In both gastric and duodenal preparations, HCO<sub>3</sub><sup>-</sup> secretion was measured for 90 min after administration of these agents. In some cases, the effects of the NO precursor L-arginine, the exogenous NO donor nitroprusside, indomethacin and atropine on the HCO<sub>3</sub><sup>-</sup> stimulatory action of L-NAME were examined. L- or D-arginine (200 mg/kg) or nitroprusside (4 mg/kg) was given i.v. 5 min before injection of L-NAME, whereas indomethacin (5 mg/kg) or atropine (1 mg/kg) was given s.c. 30 min before treatment with L-NAME. In addition, the influences of vagotomy and sensory deafferentation on the action of L-NAME were examined. Vagotomy was performed bilaterally at the subdiaphragmatic portion 60 min before administration of L-NAME. Sensory deafferentation was performed by s.c. injection of capsaicin for 3 days (20, 30 and 50 mg/kg) 2 weeks before the experiment (Yonei *et al.*, 1990). In a separate experiment, the effect of endothelin-1 (ET-1: 0.3–1 nmol/kg) on gastric HCO<sub>3</sub><sup>-</sup> secretion was also examined. ET-1 was given i.v. as a bolus injection after basal HCO<sub>3</sub><sup>-</sup> secretion had stabilized.

**Measurement of vascular permeability.** To examine the effects of L-NAME and ET-1 on gastric mucosal vascular permeability, we used a dye method to measure the extravasated amount of dye as described in a previous paper (Takeuchi *et al.*, 1987). The animals were given L-NAME (5 mg/kg) or ET-1 (1 nmol/kg) i.v., and were sacrificed 1 hr later. In each case, 1 ml of 1% Evans blue (w/w) was injected i.v. 30 min before killing. The animals were killed by bleeding from the descending aorta, the stomachs were removed and the amount of dye that had accumulated in the mucosa in 30 min was measured. The stomach was opened along the greater curvature, and the mucosa was scraped off (using two glass slides), weighed and put into a tube containing 5 ml distilled water. The extraction of dye was performed according to the modified method described by Katayama *et al.* (1978). Briefly, mucosal scrapings were soaked overnight in stoppered glass tubes containing 2 ml of 3.5 N KOH at 37°C. Then 18 ml of a mixed solution of 4 N H<sub>3</sub>PO<sub>4</sub> and acetone (1.75:16.25) was added to each tube to make up a total volume of 25 ml. The tube was shaken vigorously for a few seconds and centrifuged at 3000 rpm for 15 min. Absorbance of supernatant was measured at 620 nm on a Hitachi spectrophotometer (Mito, Ibaraki, Model 200–100). The amount of dye recovered from the mucosa was expressed in micrograms per 100 mg of tissue (μg/100 mg tissue).


**Preparation of drugs.** Drugs used were urethane (Tokyo Kasei, Tokyo, Japan), L-NAME, L-NMMA, nitroprusside, indomethacin, Evans blue (Sigma, St. Louis, MO, U.S.A.), D-NAME (Bachem, Bubendorf, Switzerland), PGE<sub>2</sub> (Funakoshi, Tokyo, Japan), L-arginine, D-arginine, atropine, capsaicin (Wako, Osaka, Japan), endothelin-1 (Peptide Institute, Osaka, Japan) and omeprazole (Hessle, Mondale, Sweden). Urethane, L-NAME, D-NAME, L-NMMA, L-arginine, D-arginine, nitroprusside, ET-1 and atropine were dissolved in saline. PGE<sub>2</sub> was first dissolved in absolute ethanol and then diluted with saline to a desired concentration. Capsaicin was dissolved in a solution consisting of 10% ethanol, 10% Tween 80 (Wako) and 80% saline (v/v). Indomethacin was suspended in saline with a drop of Tween 80, whereas omeprazole was suspended with 0.5% carboxymethylcellulose solution. Each agent was prepared immediately before use and was given in a volume of 0.1 ml per 100 g body wt in case of i.v. administration or in a volume of 0.5 ml per 100 g body wt in cases of i.p. and s.c. administration. Control animals received saline as the vehicle.

**Statistics.** Data are presented as the mean ± S.E. from 4 to 6 rats per group. Statistical analyses were performed using a two-tailed Dunnett's multiple comparison test (Dunnett, 1955), and values of P < .05 were regarded as significant.


## Results

**Effects of L-NAME on gastric and duodenal HCO<sub>3</sub><sup>-</sup> secretion.** Under our experimental conditions, the rat stomach spontaneously secreted HCO<sub>3</sub><sup>-</sup> at a steady rate of 0.25 ± 0.03–0.35 ± 0.02 μEq every 5 min in the animals given omeprazole to inhibit acid secretion. Intravenous administration of L-NAME (1, 2.5 and 5 mg/kg) produced a significant increase of gastric HCO<sub>3</sub><sup>-</sup> secretion in a dose-dependent manner, and at 5 mg/kg the rate of secretion increased from 0.23 ± 0.03 μEq/5 min to the maximal values of 0.85 ± 0.16 μEq/5 min within 20 min and remained elevated for 90 min thereafter (fig. 1). The increase in HCO<sub>3</sub><sup>-</sup> output caused by L-NAME (5 mg/kg) was 5.9 ± 1.1 μEq/hr, which is equivalent to that (4.8 ± 1.0 μEq/hr) induced by PGE<sub>2</sub> (0.3 mg/kg).


On the other hand, the proximal duodenum (1.7 cm) secreted HCO<sub>3</sub><sup>-</sup> at a steady basal rate of 0.44 ± 0.13–0.55 ± 0.12 μEq/5 min during a 90 min test period. As observed in the stomach, L-NAME administered i.v. as a single injection produced a dose-dependent increase of HCO<sub>3</sub><sup>-</sup> secretion in the duodenum. After administration of this agent at 5 mg/kg, the duodenal HCO<sub>3</sub><sup>-</sup> secretion was increased from 0.53 ± 0.07 μEq/5 min to the maximal values of 1.45 ± 0.32 μEq/5 min, about 3 times greater than basal levels, and remained elevated even 90 min later (fig. 2). ΔHCO<sub>3</sub><sup>-</sup> output induced by L-NAME was 5.2 ± 1.2 μEq/hr at 2.5 mg/kg and 8.2 ± 1.5 μEq/hr at 5 mg/kg, and



**Fig. 1.** Dose-response effects of L-NAME on gastric HCO<sub>3</sub><sup>-</sup> secretion in anesthetized rats. The animals were given omeprazole (60 mg/kg, i.p.) to inhibit acid secretion. L-NAME (1, 2.5 and 5 mg/kg) was administered i.v. as a single injection. Data are presented as the means ± S.E. of values determined every 5 min from six rats. Lower panel shows ΔHCO<sub>3</sub><sup>-</sup> output obtained for 1 hr in each group.



**Fig. 2.** Dose-response effects of L-NAME on duodenal  $\text{HCO}_3^-$  secretion in anesthetized rats. L-NAME (1, 2.5 and 5 mg/kg) was administered i.v. as a single injection. Data are presented as the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta\text{HCO}_3^-$  output obtained for 1 hr in each group.



**Fig. 3.** Effects of L-NAME, either alone or in combination with L-arginine, on arterial blood pressure in anesthetized rats. L-NAME (1, 2.5 and 5 mg/kg) was administered i.v. as a single injection. L-arginine (200 mg/kg) was given i.v. 5 min before administration of L-NAME. Data are presented as the means  $\pm$  S.E. from 4 to 5 rats per group. Statistically significant difference at  $P < .05$ ; \* from saline control, # from the group given 5 mg/kg of L-NAME.


the latter was even greater when compared to that ( $4.1 \pm 0.7 \mu\text{Eq/hr}$ ) induced by  $\text{PGE}_2$  (0.3 mg/kg).

Intravenous administration of L-NAME (1, 2.5 and 5 mg/kg) caused a marked elevation in arterial blood pressure in a dose-dependent manner (fig. 3). This pressor response was already significant at 1 mg/kg, and the mean blood pressure was increased in response to 5 mg/kg of L-NAME from  $94.3 \pm 10.5$


mm Hg to  $165.8 \pm 13.5$  mm Hg within 5 min,  $\Delta$  increase being  $75.8 \pm 8.4\%$ . The rise in blood pressure caused by L-NAME was significantly mitigated when the animals were pretreated with L-arginine (200 mg/kg) given i.v. 5 min before administration of L-NAME;  $\Delta$  increase in blood pressure was  $26.4 \pm 4.6\%$ .

In addition, both gastric and duodenal  $\text{HCO}_3^-$  secretions were stimulated by another NO synthase inhibitor, L-NMMA. As shown in figures 4 and 5, L-NMMA (50 mg/kg) administered i.v. caused a significant increase of  $\text{HCO}_3^-$  secretion, though the potency at this dose was modest and equivalent to 1/3 of that induced by L-NAME at 5 mg/kg;  $\Delta\text{HCO}_3^-$  output was  $2.4 \pm 0.7 \mu\text{Eq/hr}$  in the stomach and  $4.5 \pm 1.0 \mu\text{Eq/hr}$  in the duodenum. In contrast, administration of D-NAME, the enantiomer of L-NAME, did not significantly affect the mucosa's ability to secrete  $\text{HCO}_3^-$  in either the stomach or the duodenum, and  $\Delta\text{HCO}_3^-$  output induced by D-NAME was not significantly different from that observed in the animals given saline.

**Effects of L-arginine and nitroprusside on  $\text{HCO}_3^-$  stimulatory action of L-NAME.** To investigate whether the  $\text{HCO}_3^-$  stimulatory action of L-NAME is related to inhibition of NO biosynthesis, we examined the effects of L- and D-arginine on the  $\text{HCO}_3^-$  responses induced by L-NAME. Intravenous administration of L- or D-arginine (200 mg/kg) by itself did not affect the luminal alkalization in either the stomach or the duodenum (not shown). However, pretreatment of the animals with L-arginine significantly reduced the increase of




**Fig. 4.** Effects of various arginine analogs on  $\text{HCO}_3^-$  secretion in the stomach of anesthetized rats. Acid secretion was inhibited by omeprazole. L-NAME (5 mg/kg), D-NAME (5 mg/kg), L-NMMA (50 mg/kg) and  $\text{PGE}_2$  (0.3 mg/kg) were administered i.v. as a single injection. Data are expressed as the net  $\text{HCO}_3^-$  output and represent the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta\text{HCO}_3^-$  output obtained for 1 hr in each group. \* Statistically significant difference from saline control (lower panel), at  $P < .05$ .



**Fig. 5.** Effects of various arginine analogs on  $\text{HCO}_3^-$  secretion in the duodenum of anesthetized rats. L-NAME (5 mg/kg), D-NAME (5 mg/kg), L-NMMA (50 mg/kg) and PGE<sub>2</sub> (0.3 mg/kg) were administered i.v. as a single injection. Data are expressed as the net  $\text{HCO}_3^-$  output and represent the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta\text{HCO}_3^-$  output obtained for 1 hr in each group. \* Statistically significant difference from saline control (lower panel), at  $P < .05$ .


$\text{HCO}_3^-$  secretion induced by L-NAME (5 mg/kg);  $\Delta\text{HCO}_3^-$  output was  $1.3 \pm 0.6 \mu\text{Eq}/\text{hr}$  in the stomach, which was about 22.0% of that ( $5.9 \pm 1.1 \mu\text{Eq}/\text{hr}$ ) induced by L-NAME in control rats (figs. 6 and 7). On the other hand, prior administration of D-arginine (200 mg/kg) did not significantly affect the  $\text{HCO}_3^-$  responses to L-NAME in either the stomach or the duodenum;  $\Delta\text{HCO}_3^-$  output induced by 5 mg/kg of L-NAME in the duodenum was  $9.3 \pm 1.4 \mu\text{Eq}/\text{hr}$ , which is not significantly different from that ( $8.2 \pm 1.5 \mu\text{Eq}/\text{hr}$ ) obtained in control animals. Even in the presence of D-arginine, L-NAME (5 mg/kg) increased  $\text{HCO}_3^-$  output to the maximal values of 4 times and 3 times over the basal levels in the stomach and the duodenum, respectively. We further examined whether the exogenous NO donor nitroprusside antagonized the  $\text{HCO}_3^-$  stimulatory action of L-NAME. Intravenous administration of nitroprusside (4 mg/kg) by itself slightly suppressed the basal rate of  $\text{HCO}_3^-$  secretion and significantly inhibited the increase of  $\text{HCO}_3^-$  secretion induced by subsequent injection of L-NAME. Especially in the stomach, the increased  $\text{HCO}_3^-$  secretion by L-NAME (5 mg/kg) was completely inhibited by nitroprusside;  $\Delta\text{HCO}_3^-$  output was  $-0.6 \pm 0.1 \mu\text{Eq}/\text{hr}$ . Although  $\text{HCO}_3^-$  secretion in the duodenum was increased by L-NAME from  $0.37 \pm 0.08 \mu\text{Eq}/5 \text{ min}$  to the maximal values of  $0.76 \pm 0.26 \mu\text{Eq}/5 \text{ min}$  (198.9  $\pm$  36.1% of basal values) in the presence of nitroprusside, the  $\Delta\text{HCO}_3^-$  output ( $2.6 \pm 1.0 \mu\text{Eq}/\text{hr}$ ) induced by L-NAME was significantly lower than that observed in the absence of nitroprusside. On the other hand, both L-arginine and nitroprusside



**Fig. 6.** Effects of L-arginine, D-arginine and nitroprusside on the  $\text{HCO}_3^-$  stimulatory effect of L-NAME in the stomach of anesthetized rats. L- and D-arginine (200 mg/kg) and nitroprusside (4 mg/kg) were administered i.v. 5 min before administration of L-NAME (5 mg/kg). Data are expressed as the net  $\text{HCO}_3^-$  secretion and represent the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta\text{HCO}_3^-$  output obtained for 1 hr in each group. Statistically significant difference at  $P < .05$ ; \* from the group given saline and L-NAME (upper and lower panels), # from saline control (lower panel).

significantly antagonized the increased blood pressure response caused by L-NAME (data not shown).


**Effects of various treatments on  $\text{HCO}_3^-$  stimulatory action of L-NAME.** Subcutaneous administration of indomethacin (5 mg/kg) or atropine (1 mg/kg) alone did not significantly affect the spontaneous rate of alkaline secretion in both the stomach and the duodenum (data not shown). However, pretreatment of the animals with either of these agents significantly reduced the  $\text{HCO}_3^-$  secretion in response to L-NAME, though the effectiveness differed somewhat between stomach and duodenum (figs. 8 and 9). In the stomach,  $\Delta\text{HCO}_3^-$  output induced by L-NAME was reduced much more potently by indomethacin (85%) than by atropine (35.4%). In contrast, the  $\text{HCO}_3^-$  secretion induced by L-NAME in the duodenum was inhibited similarly by these agents, and  $\Delta\text{HCO}_3^-$  output was reduced from  $8.2 \pm 1.5 \mu\text{Eq}/\text{hr}$  to  $3.7 \pm 0.8 \mu\text{Eq}/\text{hr}$  in the presence of indomethacin and to  $4.2 \pm 1.7 \mu\text{Eq}/\text{hr}$  in the presence of atropine, reductions of 54.5% and 48.8%, respectively. The stimulatory effect of L-NAME on  $\text{HCO}_3^-$  secretion was also significantly mitigated by vagotomy. L-NAME given intravenously increased  $\text{HCO}_3^-$  secretion even in the vagotomized animals, but this effect was significantly less potent when compared with control animals. In these rats,  $\Delta\text{HCO}_3^-$  output in response to L-NAME was  $2.2 \pm 0.7 \mu\text{Eq}/\text{hr}$  in the stomach and  $1.8 \pm 0.8 \mu\text{Eq}/\text{hr}$  in the duodenum, values equiv-



**Fig. 7.** Effects of L-arginine, D-arginine and nitroprusside on the  $\text{HCO}_3^-$  stimulatory effect of L-NAME in the duodenum of anesthetized rats. L- and D-arginine (200 mg/kg) and nitroprusside (4 mg/kg) were administered i.v. 5 min before administration of L-NAME (5 mg/kg). Data are expressed as the net  $\text{HCO}_3^-$  secretion and represent the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta\text{HCO}_3^-$  output obtained for 1 hr in each group. Statistically significant difference at  $P < .05$ ; \* from the group given saline and L-NAME (upper and lower panels), # from saline control (lower panel).

alent to 35.6% and 22.0% of that induced by L-NAME in control animals, respectively. On the other hand, sensory deafferentation did not significantly affect the  $\text{HCO}_3^-$  stimulatory action of L-NAME. In these animals,  $\Delta\text{HCO}_3^-$  output induced by L-NAME was slightly decreased in both the stomach ( $3.9 \pm 0.7 \mu\text{Eq/hr}$ ) and the duodenum ( $6.7 \pm 2.1 \mu\text{Eq/hr}$ ), but these values are not significantly different from those in control animals. None of the treatments had any effect on the increase of arterial blood pressure after administration of L-NAME (not shown).

**Effect of ET-1 on gastric  $\text{HCO}_3^-$  secretion.** Because L-NAME increased  $\text{HCO}_3^-$  secretion with a marked elevation in arterial blood pressure, we examined whether such phenomena were observed with another vasoactive agent, ET-1, in the stomach. Intravenous administration of ET-1 (0.3–1 nmol/kg) significantly increased gastric  $\text{HCO}_3^-$  secretion in a dose-related manner, and at 1 nmol/kg the rate of  $\text{HCO}_3^-$  secretion was increased from  $0.26 \pm 0.02 \mu\text{Eq/5 min}$  to the maximal values of  $1.13 \pm 0.19 \mu\text{Eq/5 min}$ , which is approximately 4 times greater than control values (fig. 10). This dose of ET-1 also produced a marked elevation in arterial blood pressure, which rose from  $84.3 \pm 8.7 \text{ mm Hg}$  to the plateau values of  $156.2 \pm 11.8 \text{ mm Hg}$  within 5 min. The increased  $\text{HCO}_3^-$  response caused by ET-1 (1 nmol/kg) was almost completely blocked by vagotomy without any effect on the elevation in blood pressure (it rose from  $78.4 \pm 13.5 \text{ mm Hg}$  to  $148.6 \pm 10.2 \text{ mm Hg}$ ).




**Fig. 8.** Effects of indomethacin, atropine, vagotomy and sensory denervation on gastric  $\text{HCO}_3^-$  stimulatory action of L-NAME in anesthetized rats. Indomethacin (5 mg/kg) or atropine (1 mg/kg) was given s.c. 30 min before i.v. administration of L-NAME (5 mg/kg). Vagotomy was performed at the neck portion 1 hr before i.v. administration of L-NAME; while sensory deafferentation was performed by consecutive s.c. injections of capsaicin 2 weeks before the experiment. Data are expressed as the net  $\text{HCO}_3^-$  output and represent the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta\text{HCO}_3^-$  output obtained for 1 hr in each group. Statistically significant difference at  $P < .05$ ; \* from the group given saline and L-NAME (upper and lower panels), # from saline control (lower panel).

**Effects of L-NAME and ET-1 on mucosal vascular permeability.** To investigate the mucosal vascular permeability response to L-NAME or ET-1, we measured the amount of dye trapped in the mucosa (extravascular sites) for 30 min after intravenous injection of 1% Evans blue. In control stomachs, the amount of extravasated dye was minimal, the values being  $2.05 \pm 0.19 \mu\text{g}/100 \text{ mg tissue}$ . These values were not significantly altered by intravenous administration of either L-NAME or ET-1; the amounts of extravasated dye were  $1.88 \pm 0.08 \mu\text{g}/100 \text{ mg tissue}$  and  $2.23 \pm 0.19 \mu\text{g}/100 \text{ mg tissue}$ , respectively.

## Discussion


The local release of vasodilators such as endothelium-derived relaxing factor, identified as NO, is considered to play an essential role in the modulation of gastric mucosal integrity (Pique *et al.*, 1989; Whittle *et al.*, 1990; Moncada *et al.*, 1991). The suppression of NO biosynthesis by arginine analogs caused damage in the mucosa when they were combined with indomethacin or ablation of sensory neurons (Whittle *et al.*, 1990). The present study, however, demonstrated that the selective inhibitor of NO biosynthesis L-NAME markedly increased



**Fig. 9.** Effects of indomethacin, atropine, vagotomy and sensory denervation on duodenal HCO<sub>3</sub><sup>-</sup> stimulatory action of L-NAME in anesthetized rats. Experimental procedures are referred to figure 8. Data are expressed as the net HCO<sub>3</sub><sup>-</sup> output and represent the means  $\pm$  S.E. of values determined every 5 min from six rats. Lower panel shows  $\Delta$ HCO<sub>3</sub><sup>-</sup> output obtained for 1 hr in each group. Statistically significant difference at  $P < .05$ ; \* from the group given saline and L-NAME (upper and lower panels), # from saline control (lower panel).

HCO<sub>3</sub><sup>-</sup> secretion from the gastroduodenal mucosa and suggested that NO plays a suppressive role in the regulation of HCO<sub>3</sub><sup>-</sup> secretion.

It is known that L-NAME inhibits the biosynthesis of NO by suppressing the NO synthase by competing with the precursor L-arginine. In the present study, this NO synthase inhibitor elevated arterial blood pressure dose-dependently, and this effect was partially but significantly reversed by concurrent administration of L-arginine. Under such conditions, intravenously administered L-NAME caused a clear and persistent increase of HCO<sub>3</sub><sup>-</sup> secretion in both the stomach and the duodenum, in a dose-dependent manner. Because HCO<sub>3</sub><sup>-</sup> secretion was measured in the stomach in the presence of omeprazole, it is unlikely that the enhancement of luminal alkalization induced by L-NAME is attributable to changes in acid secretion. This contention is substantiated by the finding that L-NAME also augmented the luminal alkalization in the duodenum with no acid-secreting cells. The HCO<sub>3</sub><sup>-</sup> stimulatory action was not observed in the enantiomer D-NAME, but it was mimicked by another NO synthase inhibitor; L-NMMA. In addition, the increased HCO<sub>3</sub><sup>-</sup> response to L-NAME was significantly mitigated by prior administration of L-arginine, a substrate of endogenous NO. Such a supplementation of NO from L-arginine was found previously to enhance the endothelium-dependent vasodilation *in vitro* (Palmer *et al.*, 1988), suggesting that the currently observed effect of L-arginine is highly specific. This interpretation is also supported by the fact that the addition of D-arginine under similar experimental conditions was completely ineffective in antagonizing the HCO<sub>3</sub><sup>-</sup> responses to L-NAME. These results may suggest that



**Fig. 10.** Effect of endothelin-1 (ET-1) on gastric HCO<sub>3</sub><sup>-</sup> secretion in rats with or without bilateral vagotomy. Acid secretion was inhibited by omeprazole. ET-1 (0.3–1 nmol/kg) was administered *i.v.* as a single injection. Vagotomy was performed 1 hr before administration of ET-1 (1 nmol/kg). Data are presented as the means  $\pm$  S.E. of values determined every 5 min from five to six rats. Lower panel showed  $\Delta$ HCO<sub>3</sub><sup>-</sup> output obtained for 1 hr in each group. Statistically significant difference at  $P < .05$ ; \* from saline control (upper and lower panels), # from the group given 1 nmol/kg of ET-1 (lower panel).

stimulation of HCO<sub>3</sub><sup>-</sup> secretion by L-NAME is associated with the inhibition of NO biosynthesis. We might also speculate that NO formed endogenously may play a suppressor role in HCO<sub>3</sub><sup>-</sup> secretion under physiological conditions. In fact, the exogenous NO donor nitroprusside alone reduced the rate of HCO<sub>3</sub><sup>-</sup> secretion and totally antagonized the HCO<sub>3</sub><sup>-</sup> stimulatory effect of L-NAME in both stomach and duodenum. On the other hand, Flemstrom and Garner (1982) reported that cyclic GMP may act as an intracellular mediator in gastric HCO<sub>3</sub><sup>-</sup> secretion, whereas duodenal HCO<sub>3</sub><sup>-</sup> secretion may be mediated by cyclic AMP. NO is the endogenous stimulator of the soluble guanylate cyclase, leading to accumulation of cyclic GMP (Moncada *et al.*, 1991). Thus it remains unknown whether the effects of L-NAME or nitroprusside on HCO<sub>3</sub><sup>-</sup> secretion appeared through changes in the guanylate cyclase/cyclic GMP system in the surface epithelial cells.

Interestingly, the effect of L-NAME on HCO<sub>3</sub><sup>-</sup> secretion was significantly attenuated by indomethacin, a cyclooxygenase inhibitor. Although the HCO<sub>3</sub><sup>-</sup> response induced by L-NAME was not affected by sensory deafferentation, this response was also significantly reduced by either surgical vagotomy or pre-treatment with atropine. These results may indicate that the mechanism of HCO<sub>3</sub><sup>-</sup> secretion in response to L-NAME involves both PG-sensitive and vagal-cholinergic pathways. It is

known that vagal excitation stimulates  $\text{HCO}_3^-$  as well as acid secretions and increases the release and/or biosynthesis of PGs in the stomach of various species of animals, including rats (Cocearni *et al.*, 1967; Jonson *et al.*, 1986; Tache, 1987). As we mentioned earlier, arterial blood pressure was markedly and persistently elevated after administration of L-NAME. In general, the rise in blood pressure is accompanied by a reflex activation of the vagal nerve activity or by suppression of the sympathetic neuronal tone. Jonson and Fandriks (1989) reported that sympathetic activation *via* direct electrical stimulation of the splanchnic nerves inhibits duodenal  $\text{HCO}_3^-$  secretion in rats. Furthermore, they showed that reflex sympathetic nerve activation caused by hypotension due to bleeding inhibits duodenal  $\text{HCO}_3^-$  secretion (Jonson *et al.*, 1989). Thus it is possible to speculate that the  $\text{HCO}_3^-$  stimulatory action of L-NAME may be related to changes in parasympathetic and/or sympathetic nerve activity resulting from elevation of blood pressure, though the role of these neuronal innervations in the physiological generation of NO has not yet been elucidated. On the other hand, stimulation of capsaicin-sensitive sensory neurons is known to stimulate  $\text{HCO}_3^-$  secretion in the gastroduodenal mucosa (Takeuchi *et al.*, 1991; 1992a) and is involved in the neural reflex due to the pressor response (Maggi and Meli, 1988). However, sensory deafferentation did not influence the  $\text{HCO}_3^-$  response induced by L-NAME. Because other vasopressor agents such as norepinephrine and vasopressin are known to inhibit  $\text{HCO}_3^-$  secretion (Nylander and Flemstrom, 1986; Lenz *et al.*, 1989), it is unlikely that the elevation of blood pressure simply leads to an increase of  $\text{HCO}_3^-$  secretion. However, ET-1 caused a marked rise in gastric  $\text{HCO}_3^-$  secretion with a concomitant elevation of arterial blood pressure, similar to that caused by L-NAME, and this effect was significantly blocked by vagotomy. Further studies are needed to investigate these points by measuring  $\text{HCO}_3^-$  secretory responses to various agents affecting blood pressure and by correlating the changes in both parameters.

On the other hand, the increase of  $\text{HCO}_3^-$  output by L-NAME might be attributable to leakage of interstitial fluid and plasma into the lumen, because inhibition of NO production by L-NAME has been shown to increase both endothelial and epithelial permeability in the small intestine (Kubes, 1992; Kubes and Granger, 1992). In the present study, however, the vascular permeability in the stomach was not significantly affected by either L-NAME or ET-1. Furthermore, the  $\text{HCO}_3^-$  responses to these agents were significantly inhibited by vagotomy without any influence on the elevation of systemic blood pressure. These findings may suggest that the luminal alkalization induced by L-NAME is not simply due to leakage of  $\text{HCO}_3^-$  from the blood but that it depends partly on the vagus nerves. The explanation for the different effects of L-NAME on vascular permeability is unclear, but they may result from differences in species (feline *vs.* rat), tissue (small intestine *vs.* stomach) and/or methodology ( $^{61}\text{C}$ -EDTA *vs.* Evans blue).

MacNaughton *et al.* (1989) first demonstrated the protective effect of NO on the gastric mucosa. Later, Whittle *et al.* (1990) showed that inhibition of the biosynthesis of NO alone did not cause any lesion in the gastric mucosa but induced hemorrhagic damage when combined with indomethacin, and they suggested an interaction between NO and PG in the modulation of gastric mucosal integrity. Brown *et al.* (1992) recently reported that NO donors stimulate mucus secretion in the rat stomach. Because  $\text{HCO}_3^-$  secretion is considered to play an important

role in the mucosal defensive mechanism, in collaboration with mucus (Flemstrom and Turnberg, 1984; Garner *et al.*, 1984), it may be expected that NO has a positive effect on  $\text{HCO}_3^-$  secretion similar to that of PGs. However, the present finding that the inhibition of NO biosynthesis increased  $\text{HCO}_3^-$  secretion is contradictory to the mucosal protective role of NO, and the finding suggests that NO formed endogenously may exert a deleterious influence on the mucosa by inhibiting  $\text{HCO}_3^-$  secretion. It might be possible to speculate that endogenous NO has dual effects: that it plays a protective role mainly by increasing mucosal blood flow and exerts a proulcerogenic effect by decreasing  $\text{HCO}_3^-$  secretion. Miller *et al.* (1993) provided evidence that NO plays an inflammatory/proinflammatory role in the pathogenesis of inflammatory bowel disease of guinea pigs. At present, the physiological significance of the  $\text{HCO}_3^-$  response induced by the inhibition of NO production remains unknown, yet we observed in a preliminary study that L-NAME protected the duodenal mucosa from ulceration caused by mepirizole (unpublished data).

The current data demonstrate that the selective blockade of NO synthase by L-NAME increased  $\text{HCO}_3^-$  secretion from the gastroduodenal mucosa of anesthetized rats. This action appears to be associated with inhibition of NO biosynthesis. It may be mediated in part by endogenous PGs and may be dependent on the vagal-cholinergic innervation. Certainly, the possibility remains that NO may cause an inhibitory effect directly on the  $\text{HCO}_3^-$  transport system in the surface epithelial cells. The present data are not in keeping with the hypothesis that NO is important in the modulation of mucosal integrity (Whittle *et al.*, 1990). They suggest more complicated influences of endogenous NO on the gastroduodenal mucosa and function.

#### References

- BROWN, J. F., HANSON, P. J. AND WHITTLE, B. J. R.: Nitric oxide donors increase mucus gel thickness in rat stomach. *Eur. J. Pharmacol.* **223**: 103-104, 1992.
- COCEARNI, F., PACE-ASCIAC, C., VOLTA, F. AND WOLFF, L. S.: Effect of nerve stimulation on prostaglandin formation and release from the rat stomach. *Am. J. Physiol.* **213**: 1056-1067, 1967.
- DUNNETT, C. W.: A multiple comparison procedure for comparing several treatments with a control. *Am. J. Stat. Assoc.* **50**: 1096-1112, 1955.
- FLEMSTROM, G. AND TURNBERG, L. A.: Gastroduodenal defense mechanisms. *Clin. Gastroenterol.* **13**: 327-354, 1984.
- FLEMSTROM, G. AND GARNER, A.: Gastroduodenal  $\text{HCO}_3^-$  transport; characteristics and proposed role in acidity regulation and mucosal protection. *Am. J. Physiol.* **242**: G183-G193, 1982.
- FURCHGOTT, R. F.: The role of endothelium in the response of vascular smooth muscle to drugs. *Annu. Rev. Pharmacol. Toxicol.* **24**: 175-197, 1984.
- GARNER, A., FLEMSTROM, G., ALLEN, A., HEYLINGS, J. R. AND MCQUEEN, S.: Gastric mucosal protective mechanism: Roles of epithelial bicarbonate and mucus secretions. *Scand. J. Gastroenterol.* **19**: 79-86, 1984.
- JONSON, C. AND FANDRIKS, L.: Bleeding-induced decrease in duodenal  $\text{HCO}_3^-$  secretion in the rat is mediated *via*  $\alpha_2$  adrenoceptors. *Acta Physiol. Scand.* **130**: 387-362, 1987.
- JONSON, C., NYLANDER, O., FLEMSTROM, G. AND FANDRIKS, L.: Vagal stimulation of duodenal  $\text{HCO}_3^-$  secretion in anesthetized rats. *Acta Physiol. Scand.* **128**: 65-70, 1986.
- JONSON, C., TUNBACK-HANSON, P. AND FANDRIKS, L.: Splanchnic nerve activation inhibits the increase in duodenal  $\text{HCO}_3^-$  secretion induced by luminal acidification in the rat. *Gastroenterology* **96**: 45-49, 1989.
- KATAYAMA, S., SHIONOVA, H. AND OHTAKE, S.: A new method for extraction of extravasated dye in the skin and the influence of fasting on passive cutaneous anaphylaxis in guinea pigs and rats. *Microbiol. Immunol.* **22**: 89-101, 1978.
- KUBES, P.: Nitric oxide modulates epithelial permeability in the feline small intestine. *Am. J. Physiol.* **262**: G1138-G1142, 1992.
- KUBES P. AND GRANGER DN.: Nitric oxide modulates microvascular permeability. *Am. J. Physiol.* **262**: H611-H615, 1992.
- LENZ, H. J., FORQUIGNON, I., DRUGE, G. AND GRETEN, H.: Effects of neuropeptides on gastric acid and duodenal bicarbonate secretions in freely moving rats. *Regul. Pept.* **24**: 293-300, 1989.
- LIPPE, THI. AND HOLZER, P.: Participation of endothelium-derived nitric oxide but not prostacyclin in the gastric mucosal hyperemia due to acid back-diffusion. *Br. J. Pharmacol.* **105**: 708-714, 1992.

- MACNAUGHTON, K., CIRINO, G. AND WALLACE, J. L.: Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. *Life Sci.* **45**: 1869-1876, 1989.
- MAGGI, C. A. AND MELI, A.: The sensory-efferent functions of capsaicin-sensitive sensory neurons. *Gen. Pharmacol.* **19**: 1-43, 1988.
- MILLER, M. J. S., SADOWSKA-KROWICKA, H., CHOTINARUEMOL, S., KAKKIS, J. L. AND CLARK, D. A.: Amelioration of chronic ileitis by nitric oxide synthase inhibition. *J. Pharmacol. Exp. Ther.* **264**: 11-16, 1993.
- MONCADA, S., PALMER, R. M. J. AND HIGGS, E. A.: Nitric oxide: Physiology, pathophysiology and pharmacology. *Pharmacol. Rev.* **43**: 109-142, 1991.
- NYLANDER, O. AND FLEMSTROM, G.: Effects of alpha-adrenoceptor agonists and antagonists on duodenal surface epithelial HCO<sub>3</sub><sup>-</sup> secretion *in vivo*. *Acta Physiol. Scand.* **130**: 387-391, 1986.
- PALMER, R. M. J., REES, D. D., ASHTON, D. S. AND MONCADA, S.: L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. *Biochem. Biophys. Res. Commun.* **153**: 1251-1256, 1988.
- PIQUE, J. M., WHITTLE, B. J. R. AND ESPLUGES, J. V.: The vasodilator role of endogenous nitric oxide in the rat gastric microcirculation. *Eur. J. Pharmacol.* **174**: 293-296, 1989.
- ROBERT, A.: Prostaglandins in the gastrointestinal tract. *In* Physiology of the gastrointestinal tract, ed by L. R. Jonson, J. Christensen, M. I. Grossman, E. D. Jacobson, and S. G. Schultz, pp. 1407-1434, Raven Press, New York, 1981.
- TACHE, Y.: Central nervous system regulation of gastric acid secretion. *In* Physiology of the gastrointestinal tract. 2nd ed. ed. by L. R. Johnson, pp. 911-930, Raven Press, New York, 1987.
- TAKEUCHI, K., UESHIMA K., MATSUMOTO, J. AND OKABE, S.: Role of capsaicin-sensitive sensory nerves in acid-induced bicarbonate secretion in rat stomach. *Dig. Dis. Sci.* **37**: 737-743, 1992a.
- TAKEUCHI K, OHUCHI, T., MIYAKE, H., SUGAWARA, H. AND OKABE, S.: Effects of nitric oxide synthase inhibitors on gastric alkaline secretion in rats. *Jpn. J. Pharmacol.* **60**: 303-305, 1992b.
- TAKEUCHI, K., MATSUMOTO, J., UESHIMA, K. AND OKABE, S.: Role of capsaicin-sensitive afferent neurons in alkaline secretory response to luminal acid in the rat duodenum. *Gastroenterology* **101**: 954-961, 1991.
- TAKEUCHI, K., FURUKAWA, O., TANAKA, H. AND OKABE, S.: A new model of duodenal ulcers induced in rats by indomethacin plus histamine. *Gastroenterology* **90**: 636-645, 1986.
- TAKEUCHI, K., FURUKAWA, O., NISHIWAKI, H. AND OKABE, S.: 16,16-Dimethyl prostaglandin E<sub>2</sub> aggravates gastric mucosal injury induced by histamine in rats: Possible role of the increased mucosal vascular permeability. *Gastroenterology* **93**: 1276-1288, 1987.
- WHITTLE, B. J. R., LOPES-BERMONTE, J. AND MONCADA, S.: Regulation of gastric mucosal integrity by endogenous nitric oxide: Interactions with prostanooids and sensory neuropeptides in the rat. *Br. J. Pharmacol.* **99**: 607-611, 1990.
- YONEI, Y., HOLZER, P. AND GUTH, P. H.: Laparotomy-induced gastric protection against ethanol injury is mediated by capsaicin-sensitive sensory neurons. *Gastroenterology* **99**: 3-9, 1990.

---

Send reprint requests to: Dr. Koji Takeuchi, Department of Applied Pharmacology, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607, Japan.

---